D.E. Shaw & Co’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.4K | Buy |
16,106
+584
| +4% | +$803 | ﹤0.01% | 4383 |
|
|
2025
Q4 | $25K | Sell |
15,522
-23,604
| -60% | -$49.4K | ﹤0.01% | 4472 |
|
|
2025
Q3 | $107K | Sell |
39,126
-179,963
| -82% | -$599K | ﹤0.01% | 4344 |
|
|
2025
Q2 | $797K | Buy |
219,089
+145,928
| +199% | +$401K | ﹤0.01% | 3387 |
|
|
2025
Q1 | $140K | Sell |
73,161
-9,500
| -11% | -$19.4K | ﹤0.01% | 3980 |
|
|
2024
Q4 | $157K | Sell |
82,661
-300
| -0.4% | -$521 | ﹤0.01% | 4120 |
|
|
2024
Q3 | $110K | Buy |
+82,961
| New | +$111K | ﹤0.01% | 4242 |
|
|
2022
Q2 | – | Sell |
-22,547
| Closed | -$16K | – | 5309 |
|
|
2022
Q1 | $16K | Buy |
22,547
+8,154
| +57% | +$17.4K | ﹤0.01% | 5363 |
|
|
2021
Q4 | $33K | Buy |
+14,393
| New | +$39.2K | ﹤0.01% | 5258 |
|
|
2021
Q1 | – | Sell |
-416,583
| Closed | -$1.17M | – | 4009 |
|
|
2020
Q4 | $1.17M | Sell |
416,583
-1,613,787
| -79% | -$4.71M | ﹤0.01% | 2927 |
|
|
2020
Q3 | $5.1M | Sell |
2,030,370
-291,437
| -13% | -$2.56M | 0.01% | 1673 |
|
|
2020
Q2 | $31.5M | Buy |
2,321,807
+1,009,842
| +77% | +$10.4M | 0.04% | 548 |
|
|
2020
Q1 | $9.95M | Buy |
1,311,965
+524,334
| +67% | +$4.08M | 0.02% | 998 |
|
|
2019
Q4 | $4.98M | Buy |
787,631
+378,588
| +93% | +$1.8M | 0.01% | 1737 |
|
|
2019
Q3 | $1.6M | Sell |
409,043
-117,549
| -22% | -$504K | ﹤0.01% | 2522 |
|
|
2019
Q2 | $2.55M | Buy |
526,592
+174,805
| +50% | +$994K | ﹤0.01% | 2065 |
|
|
2019
Q1 | $2.88M | Sell |
351,787
-65,391
| -16% | -$449K | ﹤0.01% | 1913 |
|
|
2018
Q4 | $2.31M | Buy |
417,178
+312,207
| +297% | +$2.44M | ﹤0.01% | 2037 |
|
|
2018
Q3 | $927K | Buy |
104,971
+25,396
| +32% | +$227K | ﹤0.01% | 2737 |
|
|
2018
Q2 | $794K | Buy |
79,575
+47,861
| +151% | +$479K | ﹤0.01% | 2836 |
|
|
2018
Q1 | $302K | Sell |
31,714
-19,635
| -38% | -$275K | ﹤0.01% | 3146 |
|
|
2017
Q4 | $764K | Sell |
51,349
-48,588
| -49% | -$806K | ﹤0.01% | 2735 |
|
|
2017
Q3 | $1.97M | Buy |
99,937
+79,459
| +388% | +$1.22M | ﹤0.01% | 2041 |
|
|
2017
Q2 | $294K | Buy |
+20,478
| New | +$260K | ﹤0.01% | 3038 |
|
|
2017
Q1 | – | Sell |
-14,477
| Closed | -$151K | – | 3257 |
|
|
2016
Q4 | $151K | Sell |
14,477
-8,882
| -38% | -$76.5K | ﹤0.01% | 3312 |
|
|
2016
Q3 | $211K | Sell |
23,359
-1,126
| -5% | -$9.57K | ﹤0.01% | 3181 |
|
|
2016
Q2 | $183K | Sell |
24,485
-3,215
| -12% | -$28.1K | ﹤0.01% | 3204 |
|
|
2016
Q1 | $250K | Buy |
+27,700
| New | +$225K | ﹤0.01% | 3096 |
|
|
2015
Q1 | – | Sell |
-14,584
| Closed | -$170K | – | 3597 |
|
|
2014
Q4 | $170K | Buy |
+14,584
| New | +$209K | ﹤0.01% | 3833 |
|
Other funds holding AKBA
VCM
VPM
D.E. Shaw & Co's AKBA Position: Q1 2026 in Review
D.E. Shaw & Co increased its Akebia Therapeutics (AKBA) stake by 3.8% in Q1 2026, buying an estimated $803 and bringing the position to 16,106 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4383.
D.E. Shaw & Co first reported a position in AKBA in Q4 2014 and has held it in 29 quarters since. The position peaked at $31.5M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- D.E. Shaw & Co held 16,106 shares of Akebia Therapeutics worth $22.4K as of Q1 2026.
- D.E. Shaw & Co bought 584 Akebia Therapeutics shares in Q1 2026, an estimated $803.
- Akebia Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4383 holding.
- D.E. Shaw & Co first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 29 quarters since.
- D.E. Shaw & Co's Akebia Therapeutics position peaked at $31.5M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.